Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

PJ Online | News: New combination malaria treatment

Home > PJ (current issue) > News / Daily News | Search

Return to PJ Online Home Page

The Pharmaceutical Journal
Vol 268 No 7195 p557-561
27 April 2002

This article

News summary

New combination malaria treatment

A new combination preparation for the treatment of uncomplicated Plasmodium falciparum malaria, Riamet, was launched this week by Novartis Pharmaceuticals (see p566). Riamet contains two antimalarials, artemether (previously available in the United Kingdom on a named-patient basis) and lumefantrine.

The company says that the product works by attacking the parasite's life cycle at two stages. It adds that artemether has a rapid onset of action, providing early reduction in parasites, whereas lumefantrine has a slower onset of action, preventing reappearance of parasites. In addition, Riamet is effective in areas of multi-drug resistance. A course of treatment, for patients aged 12 years and over and with a body weight of 35kg or more, consists of a regimen of six doses of four tablets (ie, 24 tablets in total) over 60 hours.

Riamet has not been evaluated for the treatment of complicated malaria, including cerebral malaria or other severe manifestations such as pulmonary oedema or renal failure. It is contraindicated in patients taking any drug that inhibits cytochrome CYP3A4 or any drug that is metabolised by CYP2D6, as well as in patients taking drugs that prolong the QTc interval on electrocardiograms. Concurrent administration with other antimalarials is also contraindicated.

Dr Larry Goodyer, superintendent of Nomad Travel Pharmacy, told The Journal that Riamet is a useful treatment option, especially in the light of recent cases of travellers with falciparum malaria failing to respond to current treatment options because of resistance to antimalarials.

However, he added that because of potential drug interactions and possible cardiac problems associated with Riamet, the product does not seem suitable as standby treatment for self-administration by travellers, away from medical help, in an emergency. "Pharmacists should be aware of potential interactions," he said.

Back to Top

Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal

Citation: The Pharmaceutical Journal URI: 20006615

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Rate
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.